financetom
Business
financetom
/
Business
/
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing
Mar 22, 2024 2:37 PM

05:08 PM EDT, 03/22/2024 (MT Newswires) -- Nicholas Donoghoe, Executive Vice President, Chief Business and Strategy Officer, on March 20, 2024, sold 21,082 shares in Abbvie ( ABBV ) for $3,716,757. Following the Form 4 filing with the SEC, Donoghoe has control over a total of 55,903 shares of the company, with 55,903 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1551152/000141588924008970/xslF345X03/form4-03222024_050301.xml

Price: 179, Change: +0.55, Percent Change: +0.31

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Intellistake Says Powerbank Participating as Beta Partner in IntelliScope AI Agent Development
Intellistake Says Powerbank Participating as Beta Partner in IntelliScope AI Agent Development
Sep 24, 2025
07:55 AM EDT, 09/24/2025 (MT Newswires) -- Intellistake Technologies ( ISTKF ) said Wednesday it is developing IntelliScope, its enterprise Artificial Intelligence suite, with Nasdaq-listed Powerbank ( SUUN ) participating as a closed beta partner. Powerbank ( SUUN ), a diversified energy company, will provide long-term testing and feedback to help refine IntelliScope's first enterprise-facing agent. The IntelliScope suite is...
BT says 'government-inflicted' costs are 10 times higher in UK than Europe
BT says 'government-inflicted' costs are 10 times higher in UK than Europe
Sep 24, 2025
* BT CEO says government's November budget expected to be 'very difficult' * Says already at peak government-inflicted costs * Comes after criticism from Eli Lilly ( LLY ) boss over UK's drug pricing policy * Also says investors need fiscal and regulatory stability By Paul Sandle LONDON, Sept 24 (Reuters) - The boss of BT said the burden of...
Acadia Pharmaceuticals' ACP-101 for Hyperphagia in Prader-Willi Syndrome Fails to Meet Primary Endpoint in Phase 3 Trial
Acadia Pharmaceuticals' ACP-101 for Hyperphagia in Prader-Willi Syndrome Fails to Meet Primary Endpoint in Phase 3 Trial
Sep 24, 2025
07:54 AM EDT, 09/24/2025 (MT Newswires) -- Acadia Pharmaceuticals ( ACAD ) said Wednesday its ACP-101, or intranasal carbetocin, therapy candidate for patients with hyperphagia in Prader-Willi syndrome did not meet its primary efficacy endpoint in a phase 3 trial. The therapy candidate failed to demonstrate a 'statistically significant improvement over placebo' from baseline to week 12. Acadia plans to...
Cidara Says Phase 3 Trial of Influenza Prevention Drug CD388 to Begin in September
Cidara Says Phase 3 Trial of Influenza Prevention Drug CD388 to Begin in September
Sep 24, 2025
07:55 AM EDT, 09/24/2025 (MT Newswires) -- Cidara Therapeutics ( CDTX ) said Wednesday it will start enrolling patients for a phase 3 trial of CD388 by the end of September following its end-of-phase 2 meeting with the US Food and Drug Administration. The company said it is accelerating and expanding its development plan, seeking biologics license application approval based...
Copyright 2023-2026 - www.financetom.com All Rights Reserved